DK2802606T3 - Forøgelse af transport af terapeutiske molekyler hen over blod-hjerne-barrieren - Google Patents
Forøgelse af transport af terapeutiske molekyler hen over blod-hjerne-barrieren Download PDFInfo
- Publication number
- DK2802606T3 DK2802606T3 DK13702529.2T DK13702529T DK2802606T3 DK 2802606 T3 DK2802606 T3 DK 2802606T3 DK 13702529 T DK13702529 T DK 13702529T DK 2802606 T3 DK2802606 T3 DK 2802606T3
- Authority
- DK
- Denmark
- Prior art keywords
- binding
- domain
- molecule
- antibody
- binding molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (21)
1. Bindingsmolekyle, der er et kimært protein, som omfatter mindst ét farmakologisk aktivt middel, mindst to bindingssteder, der er omfattet i enkeltdomæneantistoffer, som binder til TMEM30A, og en Fc-region, der omfatter en første Fc-gruppe og en anden Fc-gruppe, hvor de mindst to bindingssteder, som binder til TMEM30A, hver især i) direkte eller ii) via en mellemliggende aminosyresekvens er fusioneret til den N-terminale ende af henholdsvis den første Fc-gruppe og den anden Fc-gruppe, hvor Fc-regionen specifikt binder til FcRn-receptoren.
2. Bindingsmolekyle ifølge krav 1, hvor den første Fc-gruppe og den anden Fc-gruppe hver især omfatter et CH2-domæne og et CH3-domæne.
3. Bindingsmolekyle ifølge kravene 1 eller 2, hvor den første Fc-gruppe og den anden Fc-gruppe hver især omfatter en hængselregion, et CFI2-domæne og et CFI3-domæne.
4. Bindingsmolekyle ifølge et hvilket som helst af kravene 1 til 3, hvor Fc-regionen er fra et IgG-antistof.
5. Bindingsmolekyle ifølge et hvilket som helst af de foregående krav, hvor (a) de mindst to bindingssteder omfatter FC5-aminosyresekvensen, eller (b) de mindst to bindingssteder består af FC5-aminosyresekvensen.
6. Bindingsmolekyle ifølge et hvilket som helst af de foregående krav, hvor den første og/eller den anden Fc-gruppe har en mutation i et konserveret N-forbundet glycosyleringssted, der reducerer glycosylering af den første og/eller den anden Fc-gruppe.
7. Bindingsmolekyle ifølge et hvilket som helst af de foregående krav, der omfatter SEQ ID NO:1.
8. Bindingsmolekyle ifølge krav 1, hvor bindingsmolekylet omfatter mindst tre bindingssteder, som er omfattet i enkeltdomæneantistoffer, der binder til TMEM30A, mere fortrinsvis hvor bindingsmolekylet omfatter mindst fire bindingssteder, som er omfattet i enkeltdomæneantistoffer, der binder til TMEM30A.
9. Bindingsmolekyle ifølge krav 1, hvor (a) de mindst to bindingssteder er genetisk fusioneret direkte til henholdsvis den første og den anden Fc-gruppe, (b) de mindst to bindingssteder via en mellemliggende aminosyresekvens, der omfatter en peptidlinker, er genetisk fusioneret til henholdsvis den første og den anden Fc-gruppe, eller (c) de mindst to bindingssteder via en mellemliggende aminosyresekvens, der består af en peptidlinker, er genetisk fusioneret til henholdsvis den første og den anden Fc-gruppe.
10. Bindingsmolekyle ifølge krav 1, hvor de mindst to bindingssteder via en aminosyresekvens, der omfatter en peptidlinker, er fusioneret til den N-terminale ende af henholdsvis den første og den anden Fc-gruppe, og hvor den første og den anden Fc-gruppe er forskellige fra hinanden.
11. Bindingsmolekyle ifølge krav 1, hvor (a) ét af de mindst to bindingssteder er fusioneret til den N-terminale ende af et scFc-molekyle, eller (b) det mindst ene farmakologisk aktive middel er fusioneret til den C-terminale ende af Fc-regionen.
12. Bindingsmolekyle ifølge krav 1, hvor det mindst ene farmakologisk aktive middel er en lille kemisk enhed, fortrinsvis hvor den lille kemiske enhed er fusioneret til bindingsmolekylet i en cysteinrest, mere fortrinsvis hvor cysteinresten er en genmanipuleret cysteinrest.
13. Bindingsmolekyle ifølge krav 1, hvor det mindst ene farmakologisk aktive middel er et polypeptid, fortrinsvis hvor det mindst ene farmakologisk aktive middel omfatter et antigenbindingssted, mere fortrinsvis hvor antigenbindingsstedet er afledt af et ikke-TMEM30-bindende antistof.
14. Bindingsmolekyle ifølge krav 13, hvor det farmakologisk aktive middel er valgt fra gruppen bestående af et scFv-molekyle, et Fab-molekyle og et enkeltdomæneantistof.
15. Bindingsmolekyle ifølge krav 1, hvor det mindst ene farmakologisk aktive middel er genetisk fusioneret til bindingsmolekylet, fortrinsvis hvor de mindst to bindingssteder er genetisk fusioneret via en mellemliggende aminosyresekvens, der omfatter VH-domænet i et antistofmolekyle, eller hvor de mindst to bindingssteder er genetisk fusioneret via en mellemliggende aminosyresekvens, der omfatter VL-domænet i et antistofmolekyle, fortrinsvis hvor den mellemliggende aminosyresekvens endvidere omfatter en peptidlinker.
16. Bindingsmolekyle ifølge krav 1, hvor det mindst ene farmakologisk aktive middel er kovalent bundet til bindingsmolekylet.
17. Bindingsmolekyle ifølge krav 15, hvor (a) de mindst to bindingssteder er genetisk fusioneret til den N-terminale ende af et VH-domæne i et intakt antistofmolekyle, eller (b) de mindst to bindingssteder er genetisk fusioneret til den N-terminale ende af et VL-domæne i et intakt antistofmolekyle.
18. Bindingsmolekyle ifølge krav 1, hvor de mindst to bindingssteder er genetisk fusioneret til den N-terminale ende af et VH-domæne og et VL-domæne i et intakt antistofmolekyle.
19. Bindingsmolekyle ifølge krav 1, hvor det farmaceutisk aktive middel er valgt fra gruppen bestående af et neuroaktivt peptid, en lille kemisk enhed og en variabel region i et antistof, der binder til et mål i det centrale nervesystem.
20. Bindingsmolekyle ifølge et hvilket som helst af kravene 1-19 til anvendelse ved behandling af en neurologisk lidelse.
21. Bindingsmolekyle til anvendelse ifølge krav 20, hvor den neurologiske lidelse er en lagringslidelse, kronisk smerte, epilepsi, multipel sklerose, en proteinopati eller en demyeliniserende lidelse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261585039P | 2012-01-10 | 2012-01-10 | |
| PCT/US2013/021041 WO2013106577A2 (en) | 2012-01-10 | 2013-01-10 | Enhancement of transport of therapeutic molecules across the blood brain barrier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2802606T3 true DK2802606T3 (da) | 2018-06-25 |
Family
ID=47633561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13702529.2T DK2802606T3 (da) | 2012-01-10 | 2013-01-10 | Forøgelse af transport af terapeutiske molekyler hen over blod-hjerne-barrieren |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9676849B2 (da) |
| EP (1) | EP2802606B1 (da) |
| JP (1) | JP6247226B2 (da) |
| KR (1) | KR102104686B1 (da) |
| CN (1) | CN104159922B (da) |
| AU (1) | AU2013207927B2 (da) |
| BR (1) | BR112014016887A2 (da) |
| CA (1) | CA2860579A1 (da) |
| CY (1) | CY1120419T1 (da) |
| DK (1) | DK2802606T3 (da) |
| EA (1) | EA201491346A1 (da) |
| ES (1) | ES2677111T3 (da) |
| HK (1) | HK1203977A1 (da) |
| HR (1) | HRP20180937T1 (da) |
| HU (1) | HUE039033T2 (da) |
| IL (1) | IL233246B (da) |
| LT (1) | LT2802606T (da) |
| MX (1) | MX350378B (da) |
| NZ (1) | NZ626620A (da) |
| PL (1) | PL2802606T3 (da) |
| PT (1) | PT2802606T (da) |
| SI (1) | SI2802606T1 (da) |
| TR (1) | TR201809743T4 (da) |
| WO (1) | WO2013106577A2 (da) |
| ZA (1) | ZA201404873B (da) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ701040A (en) | 2012-07-04 | 2017-02-24 | Hoffmann La Roche | Covalently linked antigen-antibody conjugates |
| RU2682754C2 (ru) | 2014-01-03 | 2019-03-21 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью |
| WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
| MX373856B (es) | 2014-01-03 | 2025-03-04 | Hoffmann La Roche | Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos. |
| PE20161311A1 (es) * | 2014-03-06 | 2016-11-25 | Nat Res Council Canada | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. |
| US10100117B2 (en) * | 2014-03-06 | 2018-10-16 | National Research Council Of Canada | Insulin-like growth factor 1 receptor-specific antibodies and uses thereof |
| AU2014385799B2 (en) * | 2014-03-06 | 2020-10-22 | National Research Council Of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
| JP6391318B2 (ja) * | 2014-06-27 | 2018-09-19 | 学校法人順天堂 | アルツハイマー病予防治療薬のスクリーニング法 |
| JP2018505662A (ja) | 2014-12-19 | 2018-03-01 | メッドイミューン・リミテッド | 血液脳関門輸送分子およびそれらの使用 |
| US10654917B2 (en) | 2015-01-29 | 2020-05-19 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| EP3481870A4 (en) * | 2016-07-06 | 2020-03-11 | National Research Council of Canada | HUMANIZED ANTIBODIES CROSSING THE HEMATOENCEPHALIC BARRIER AND USES THEREOF |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| WO2018109663A1 (en) | 2016-12-12 | 2018-06-21 | National Research Council Of Canada | Antibody variants transmigrating the blood-brain barrier and uses thereof |
| US11702466B2 (en) * | 2017-01-30 | 2023-07-18 | National Research Council Of Canada | Fusion protein comprising a blood-brain barrier (BBB)-crossing single domain antibody Fc5, an immunoglobulin Fc fragment and a beta-amyloid binding polypeptide (ABP) |
| WO2019036725A2 (en) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | PEPTIDE INHIBITORS OF TAU AGGREGATION |
| JP7369127B2 (ja) | 2017-12-28 | 2023-10-25 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体 |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| US11952432B2 (en) | 2018-02-07 | 2024-04-09 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
| EP3806889A4 (en) * | 2018-06-18 | 2022-07-13 | Anwita Biosciences, Inc. | CYTOKI FUSION PROTEINS AND USES THEREOF |
| EP3586860A1 (en) * | 2018-06-22 | 2020-01-01 | Universität Ulm | Complement inhibitors and uses thereof |
| US20210161993A1 (en) * | 2018-09-12 | 2021-06-03 | Pvp Labs Pte. Ltd. | Method for accelerated healing of burn wounds |
| AU2019354965B2 (en) | 2018-10-04 | 2025-03-27 | University Of Rochester | Improvement of glymphatic delivery by manipulating plasma osmolarity |
| EA202191179A1 (ru) * | 2018-10-29 | 2021-09-09 | Байоджен Ма Инк. | Гуманизированные и стабилизированные варианты fc5 для улучшения транспорта через гематоэнцефалический барьер |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| CN113284553B (zh) * | 2021-05-28 | 2023-01-10 | 南昌大学 | 一种用于治疗药物成瘾的药物靶点结合能力测试方法 |
| JP2024543867A (ja) | 2021-12-02 | 2024-11-26 | リンノ ファーマシューティカルズ インコーポレイテッド | トランスフェリン結合抗体及びその使用 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1166947A (en) | 1914-10-05 | 1916-01-04 | Paramount Hosiery Form Drying Company | Hosiery-finishing apparatus. |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US4889919A (en) | 1986-08-13 | 1989-12-26 | Zymogenetics, Inc. | Biologically active PDGF derived A-chain homodimers |
| US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
| US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
| IL78444A (en) | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
| EP0256654B1 (en) | 1986-07-07 | 1996-09-18 | Centocor, Inc. | Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen |
| NO873164L (no) | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
| IL84285A (en) | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| CA1339445C (en) | 1986-11-12 | 1997-09-09 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and method of use |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK0474744T3 (da) | 1989-05-22 | 1994-11-21 | Zymogenetics Inc | PDGF-alfa-receptor |
| US5061786A (en) | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
| EP0417563B1 (de) | 1989-09-12 | 2000-07-05 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2040099A1 (en) | 1990-05-01 | 1991-11-02 | Mariano Barbacid | Tyrosine kinase negative trkb |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5453491A (en) | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| JPH04334377A (ja) | 1990-12-31 | 1992-11-20 | Akzo Nv | 酸−不安定性リンカー分子 |
| EP0509826A1 (en) | 1991-04-19 | 1992-10-21 | Schering Corporation | Subunit of the human interleukin 3 receptor |
| US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
| US5348856A (en) | 1991-07-08 | 1994-09-20 | E. R. Squibb & Sons, Inc. | DNA encoding TRKC protein |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| DE69333082T2 (de) | 1992-02-11 | 2004-05-06 | Cell Genesys, Inc., Foster City | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| WO1997009427A1 (en) | 1995-09-08 | 1997-03-13 | Genentech, Inc. | Vegf-related protein |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| EP0922102B1 (en) | 1996-07-03 | 2010-04-21 | Genentech, Inc. | Hepatocyte growth factor receptor agonists and uses thereof |
| US6159462A (en) | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
| WO1998019705A1 (en) | 1996-11-05 | 1998-05-14 | Bristol-Myers Squibb Company | Branched peptide linkers |
| ATE319745T1 (de) | 1997-05-21 | 2006-03-15 | Biovation Ltd | Verfahren zur herstellung von nicht-immunogenen proteinen |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| EP1141015B1 (en) | 1999-01-06 | 2009-07-15 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
| WO2000040613A1 (en) | 1999-01-06 | 2000-07-13 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
| US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
| SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
| EP1328626B1 (en) * | 2000-05-26 | 2013-04-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| CA2444854A1 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| NZ550772A (en) | 2004-05-21 | 2009-10-30 | Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
| AU2005307789A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| WO2007036021A1 (en) * | 2005-09-27 | 2007-04-05 | National Research Council Of Canada | Blood-brain barrier epitopes and uses thereof |
| WO2007095338A2 (en) * | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
| CN101802197A (zh) | 2007-05-14 | 2010-08-11 | 比奥根艾迪克Ma公司 | 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法 |
| EA201201227A1 (ru) | 2010-03-03 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Бипаратопные а-бета-связывающие полипептиды |
| WO2011127580A1 (en) * | 2010-04-14 | 2011-10-20 | National Research Council Of Canada | Compositions and methods for brain delivery of analgesic peptides |
-
2013
- 2013-01-10 JP JP2014552303A patent/JP6247226B2/ja not_active Expired - Fee Related
- 2013-01-10 DK DK13702529.2T patent/DK2802606T3/da active
- 2013-01-10 EA EA201491346A patent/EA201491346A1/ru unknown
- 2013-01-10 KR KR1020147018724A patent/KR102104686B1/ko not_active Expired - Fee Related
- 2013-01-10 NZ NZ626620A patent/NZ626620A/en not_active IP Right Cessation
- 2013-01-10 HU HUE13702529A patent/HUE039033T2/hu unknown
- 2013-01-10 US US14/370,828 patent/US9676849B2/en active Active
- 2013-01-10 ES ES13702529.2T patent/ES2677111T3/es active Active
- 2013-01-10 EP EP13702529.2A patent/EP2802606B1/en active Active
- 2013-01-10 MX MX2014008365A patent/MX350378B/es active IP Right Grant
- 2013-01-10 CN CN201380004989.7A patent/CN104159922B/zh not_active Expired - Fee Related
- 2013-01-10 AU AU2013207927A patent/AU2013207927B2/en not_active Ceased
- 2013-01-10 LT LTEP13702529.2T patent/LT2802606T/lt unknown
- 2013-01-10 CA CA2860579A patent/CA2860579A1/en active Pending
- 2013-01-10 SI SI201331060T patent/SI2802606T1/en unknown
- 2013-01-10 TR TR2018/09743T patent/TR201809743T4/tr unknown
- 2013-01-10 BR BR112014016887A patent/BR112014016887A2/pt not_active Application Discontinuation
- 2013-01-10 PT PT137025292T patent/PT2802606T/pt unknown
- 2013-01-10 WO PCT/US2013/021041 patent/WO2013106577A2/en active Application Filing
- 2013-01-10 PL PL13702529T patent/PL2802606T3/pl unknown
-
2014
- 2014-06-19 IL IL233246A patent/IL233246B/en active IP Right Grant
- 2014-07-01 ZA ZA2014/04873A patent/ZA201404873B/en unknown
-
2015
- 2015-05-11 HK HK15104429.6A patent/HK1203977A1/xx not_active IP Right Cessation
-
2018
- 2018-06-18 HR HRP20180937TT patent/HRP20180937T1/hr unknown
- 2018-07-11 CY CY20181100721T patent/CY1120419T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2802606A2 (en) | 2014-11-19 |
| IL233246B (en) | 2018-07-31 |
| EP2802606B1 (en) | 2018-04-25 |
| HK1203977A1 (en) | 2015-11-06 |
| US9676849B2 (en) | 2017-06-13 |
| LT2802606T (lt) | 2018-10-10 |
| KR102104686B1 (ko) | 2020-04-24 |
| NZ626620A (en) | 2016-07-29 |
| HRP20180937T1 (hr) | 2018-08-10 |
| AU2013207927B2 (en) | 2017-11-02 |
| MX2014008365A (es) | 2014-10-06 |
| ZA201404873B (en) | 2018-12-19 |
| PL2802606T3 (pl) | 2018-09-28 |
| PT2802606T (pt) | 2018-07-13 |
| IL233246A0 (en) | 2014-08-31 |
| BR112014016887A2 (pt) | 2018-08-14 |
| CA2860579A1 (en) | 2013-07-18 |
| CY1120419T1 (el) | 2019-07-10 |
| US20150210762A1 (en) | 2015-07-30 |
| CN104159922A (zh) | 2014-11-19 |
| AU2013207927A1 (en) | 2014-07-17 |
| TR201809743T4 (tr) | 2018-07-23 |
| KR20140112497A (ko) | 2014-09-23 |
| HUE039033T2 (hu) | 2018-12-28 |
| WO2013106577A3 (en) | 2013-11-21 |
| JP2015509097A (ja) | 2015-03-26 |
| WO2013106577A2 (en) | 2013-07-18 |
| MX350378B (es) | 2017-09-05 |
| JP6247226B2 (ja) | 2017-12-13 |
| CN104159922B (zh) | 2018-03-02 |
| EA201491346A1 (ru) | 2014-11-28 |
| ES2677111T3 (es) | 2018-07-30 |
| SI2802606T1 (en) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2802606T3 (da) | Forøgelse af transport af terapeutiske molekyler hen over blod-hjerne-barrieren | |
| EP2655624B1 (en) | Linker peptides and polypeptides comprising same | |
| ES2998890T3 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| CN107428835B (zh) | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 | |
| ES2864160T3 (es) | Módulos lanzadera de la barrera hematoencefálica monovalentes | |
| JP7427046B2 (ja) | Ｂｄｎｆを含む融合蛋白質 | |
| US7820165B2 (en) | Compositions and methods of producing hybrid antigen binding molecules and uses thereof | |
| US20240317888A1 (en) | Antibodies that bind psma and gamma-delta t cell receptors | |
| KR20110127224A (ko) | 개선된 항-혈청 알부민 결합 변이체 | |
| KR20210045999A (ko) | 인간 Tim-3에 대한 모노클로날 항체 | |
| KR20220130687A (ko) | Ltbr 및 edb 결합 도메인을 포함하는 다중특이성 결합 분자 및 이의 용도 | |
| CN110945029A (zh) | 用于治疗的药剂、用途和方法 | |
| CN116888153A (zh) | 与γ-δT细胞受体结合的抗体 | |
| JP2023541816A (ja) | 自己免疫性疾患および癌を治療するための方法および組成物 | |
| CN119698294A (zh) | 结合γ-δT细胞受体的变体抗体 | |
| JP2023515196A (ja) | 脂肪酸分子とコンジュゲートされた抗体及びその使用 | |
| JP2024505673A (ja) | 電荷対を有する二重特異性抗体及びその使用 | |
| JP2024505072A (ja) | イヌ科動物抗体の定常領域における変異 | |
| EA040195B1 (ru) | Усиление транспорта терапевтических молекул через гематоэнцефалический барьер | |
| WO2024253595A1 (en) | MULTISPECIFIC ANTIGEN BINDING PROTEIN AGAINST EpCAM |